Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NewAmsterdam Pharma Co N.V (NAMS) Capital Expenditures: 2020-2024

Historic Capital Expenditures for NewAmsterdam Pharma Co N.V (NAMS) over the last 5 years, with Dec 2024 value amounting to $672,000.

  • NewAmsterdam Pharma Co N.V's Capital Expenditures fell 44.00% to $42,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $149,000, marking a year-over-year decrease of 77.83%. This contributed to the annual value of $672,000 for FY2024, which is 2700.00% up from last year.
  • NewAmsterdam Pharma Co N.V's Capital Expenditures amounted to $672,000 in FY2024, which was up 2,700.00% from $24,000 recorded in FY2023.
  • In the past 5 years, NewAmsterdam Pharma Co N.V's Capital Expenditures ranged from a high of $672,000 in FY2024 and a low of $14,843 during FY2020.
  • In the last 3 years, NewAmsterdam Pharma Co N.V's Capital Expenditures had a median value of $221,000 in 2022 and averaged $305,667.
  • As far as peak fluctuations go, NewAmsterdam Pharma Co N.V's Capital Expenditures plummeted by 89.14% in 2023, and later spiked by 2,700.00% in 2024.
  • NewAmsterdam Pharma Co N.V's Capital Expenditures (Yearly) stood at $14,843 in 2020, then skyrocketed by 61.69% to $24,000 in 2021, then surged by 820.83% to $221,000 in 2022, then slumped by 89.14% to $24,000 in 2023, then soared by 2,700.00% to $672,000 in 2024.